γ-Secretase inhibitors have been considered promising drug candidates against Alzheimer's disease (AD) due to their ability to reduce amyloid-β (Aβ) production. However, clinical trials have been halted due to lack of clinical efficacy and/or side effects. Recent in vitro studies suggest that low doses of γ-secretase inhibitors may instead increase Aβ production. Using a stem cell-derived human model of cortical neurons and low doses of the γ-secretase inhibitor DAPT, the effects on a variety of Aβ peptides were studied using mass spectrometry. One major focus was to develop a novel method for specific detection of oligomeric Aβ (oAβ), and this was used to study the effects of low-dose γ-secretase inhibitor treatment on intracellular oAβ accumulation. Low-dose treatment (2 and 20 nM) with DAPT increased the secretion of several Aβ peptides, especially Aβx-42. Furthermore, using the novel method for oAβ detection, we found that 2 nM DAPT treatment of cortical neurons resulted in increased oAβ accumulation. Thus, low dose-treatment with DAPT causes both increased production of long, aggregation-prone Aβ peptides and accumulation of intracellular Aβ oligomers, both believed to contribute to AD pathology.
Introduction
Plaques, composed of the aggregation-prone peptide amyloid-β (Aβ), are key pathological hallmarks of Alzheimer's disease (AD). Ever since the amyloid cascade hypothesis was proposed in 1991 (Hardy and Allsop, 1991) , much research on AD pathogenesis has focused on the mechanisms behind Aβ generation and degradation. In line with this, several drug candidates have been developed, aiming at reducing Aβ production by inhibiting or modulating the key enzymes involved in the production of Aβ. Aβ is generated by sequential cleavage of the amyloid precursor protein (APP) by β-secretase followed by γ-secretase (Blennow et al., 2006) , and therefore both β-and γ-secretase inhibitors have been proposed as possible treatments for AD.
The first γ-secretase inhibitor (GSI) showing in vivo reduction of Aβ in the brain was N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) (Dovey et al., 2001) , although failing to reach clinical testing. It has since then been widely used in vitro to study different aspects of APP cleavage and Aβ generation. Other GSIs, such as semagacestat (also called LY-450139) and avagacestat, have been developed thereafter, but the phase III trial with semagacestat and the phase II trial with avagacestat were struck by side effects (Coric et al., 2012; Imbimbo et al., 2011) , and even lead to deteriorating cognition (Doody et al., 2013) . γ-Secretase has many other substrates besides APP including NOTCH, a protein important during neuronal development and maintenance (Imayoshi et al., 2010) . The inhibition of NOTCH cleavage may therefore be one cause for the severe side effects of GSIs (Henley et al., 2014) , as could accumulation of toxic APP cleavage products (Mitani et al., 2012) . In addition, upon treatment with GSIs, it has been reported that the initial decrease in Aβ levels in blood is followed by an increase in Aβ levels, as the drug concentration in plasma decreases (De Strooper, 2014) . Interestingly, both in vivo and in vitro studies have shown that low doses of both semagacestat and DAPT increase Aβ levels, instead of decreasing them (Barnwell et al., 2014; Lanz et al., 2006) .
Because the Aβ peptide is hydrophobic, accumulation causes it to aggregate into soluble oligomers and further into insoluble fibrils, the constituent of Aβ plaques (Blennow et al., 2006) . It has been reported that deposits of extracellular Aβ do not correlate with cognitive symptoms and that Aβ plaques may be present several years before symptom onset in AD (Perrin et al., 2009) . Additionally, compact plaques consisting of Aβ fibrils are found in non-demented individuals (Guillozet et al., 2003) , and it is now believed that the soluble oligomeric Aβ (oAβ) is the most toxic species (Benilova et al., 2012) . Soluble forms of synthetic as well as naturally produced oAβ are toxic to cells in vitro and in vivo (Hoshi et al., 2003; Lambert et al., 1998; Takuma et al., 2004) , and have the ability to disrupt cognitive function (Cleary et al., 2005) .
Due to the importance of oAβ in AD pathogenesis, there is a need for reliable methods to detect oAβ. Previously, oligomer-specific antibodies such as the polyclonal anti-oligomer antibody A11, have been developed. However, this antibody also detects oligomers from other proteins such as insulin, prion protein and lysozyme (Kayed et al., 2003) . Different dyes, such as congo red and thioflavin S/T stain Aβ fibrils and protofibrils, but do not recognize smaller oligomers of Aβ (Walsh et al., 1999) . In addition, small probes (luminescent conjugated oligothiophenes; LCOs) have been shown to bind to aggregated Aβ in diffuse plaques (Nilsson et al., 2006) , and seem to detect smaller Aβ aggregates than traditional dyes, but are not specific for Aβ aggregates. It is therefore of importance to develop new sensitive and specific methods for detection of oAβ. Recently, a method based on the proximity ligation assay (PLA) for detection of α-synuclein oligomers was described (Roberts et al., 2015) . Here, we used the same approach to develop an assay for detection and quantification of intracellular oAβ. This oAβ method, along with immunochemical quantification of Aβx-38, Aβx-40, and Aβx-42 and immunoprecipitation-mass spectrometry (IP-MS) analysis of secreted Aβ peptides, was used to examine the effects of lowdose γ-secretase inhibition on production of a variety of Aβ peptides and the potential accumulation of intracellular oAβ in a previously established human neuronal model (Shi et al., 2012) that produces all relevant Aβ peptides (Bergström et al., 2016) .
Results

Low-dose γ-secretase inhibition increases secretion of Aβ42 without affecting intracellular C-terminal fragment of APP
To test the hypothesis that low-dose γ-secretase inhibition increases production of long Aβ peptides, human induced pluripotent stem cell (iPSC)-derived cortical neurons were treated with 2, 20 or 200 nM DAPT for 48 h. Thereafter, cell-conditioned media were collected and analysed for secreted Aβx-38, Aβx-40, and Aβx-42. As the basal levels of Aβ secretion varied depending on the age of the neurons used in each repeat, the relative changes are presented here for statistical analysis. The actual concentrations of secreted Aβ from each experiment are available in Supplementary Fig. 1 . Treatment with 2 or 20 nM DAPT tended to increase the secreted levels of Aβx-38 (Fig. 1A) and Aβx-40 (Fig. 1B ) compared with control, although the difference did not reach statistical significance, while secretion of Aβx-42 (Fig. 1C) was significantly increased upon treatment with 2 and 20 nM DAPT. Treatment with 200 nM DAPT significantly decreased the secretion of all three peptides compared with control. This shows that low-dose treatment with the γ-secretase inhibitor DAPT significantly increased the secretion of Aβx-42, whereas a higher concentration (200 nM) decreased the secretion of all three Aβ peptides.
In addition, the effect of DAPT treatment on the Aβx-42/38 and Aβx-42/40 ratios was investigated. Treatment with 20 nM DAPT increased the Aβ42/38 ratio, which was further increased upon treatment with 200 nM DAPT (Fig. 1D) . Treatment with 200 nM DAPT also significantly increased the Aβx-42/40 ratio (Fig. 1E) . To investigate if the increased secretion of Aβ was accompanied by a change in the APP Cterminal fragment (the substrate for γ-secretase), western blot analysis was performed on cell lysates. While treatment with 2 or 20 nM DAPT did not change the levels of intracellular C-terminal fragments compared with control, they were significantly increased upon 200 nM DAPT treatment (Fig. 1F ).
Low-dose γ-secretase inhibition reveals different patterns of Aβ peptide secretion
From earlier studies, we know that a number of Aβ peptides of varying length can be found in CSF and cell-conditioned media, and that the peptides are differently affected by secretase inhibition (Portelius et al., 2010; Portelius et al., 2011) . However, this has not been investigated in human iPSC-derived neurons, why we performed a more detailed investigation of the effects of low-dose GSI treatment on Aβ peptide secretion by analysing cell-conditioned media from cortical neurons using IP-MS. The relative levels of all secreted peptides were calculated by dividing the peak area of each peptide by the total peak areas for all peptides detected. Relative secretion levels of the short Aβ1-16 ( Fig. 2A) was not affected by 2 or 20 nM DAPT but was, as expected (Portelius et al., 2009) , increased when cells were exposed to 200 nM DAPT. This supports that γ-secretase is not involved in the production of Aβ1-16, but rather that the decrease in γ-secretase activity allows for an increased activity of other secretases. In contrast, Aβ1-17 was significantly decreased upon treatment with 200 nM DAPT, with a trend towards decrease upon 20 nM DAPT treatment (Fig. 2B) . A similar tendency was seen for Aβ1-19 (Fig. 2C) , although not reaching statistical significance, indicating that production of these two peptides may be γ-secretase-dependent. Interestingly, Aβ1-20 had a similar secretion pattern as Aβ1-16, with a tendency to increase upon DAPT treatment (Fig. 2D) . Secretion of Aβ1-33 was not significantly decreased by low doses of DAPT, but completely abolished upon treatment with 200 nM (Fig. 2E) .
Aβ1-34 has earlier been shown to be the Aβ peptide most sensitive to γ-secretase inhibition (Portelius et al., 2010) . We found a direct statistically significant dose-dependent decrease in secretion of Aβ1-34 (Fig. 2F ) upon treatment with increasing doses of DAPT, showing that 2 nM DAPT is indeed inhibiting γ-secretase. To further verify this, we investigated the mRNA expression of HES1, which is stimulated upon γ-secretase dependent cleavage and activation of NOTCH (Kageyama et al., 2008) , after treatment with 2, 20 and 200 nM DAPT. All three doses decreased HES1 expression to a similar level, compared to control ( Supplementary Fig. 2 ), supporting that 2 nM DAPT is enough to reduce γ-secretase activity.
The longer peptides Aβ5-40 (Fig. 2G ), Aβ1-37 (Fig. 2H ), Aβ1-38 ( Fig. 2I ), Aβ1-39 ( Fig. 2J ), Aβ1-40 ( Fig. 2K ) and Aβ1-42 ( Fig. 2L ) all follow the same trend, however statistically non-significant, towards increased secretion upon treatment with 2 and 20 nM DAPT, but with strongly reduced secretion upon treatment with 200 nM DAPT.
A novel method to detect oligomeric Aβ
As low doses of the γ-secretase inhibitor DAPT increase the production/secretion of longer, more aggregation-prone Aβ peptides and decrease, or do not affect, the production of shorter, we were interested in investigating the effects of low-dose γ-secretase inhibition on intracellular oAβ accumulation. A novel method for oAβ detection was developed using proximity ligation assay (PLA; Duolink), by conjugating PLUS and MINUS Duolink probes to the N-terminal specific Aβ antibody 82E1 (Horikoshi et al., 2004) . The method was optimized on oAβ1-42 ( Supplementary Fig. 1A ) fed to SH-SY5Y cells, as previously described (Domert et al., 2014) . Using immunocytochemistry, it was evident that the 82E1 antibody was able to detect intracellular Aβ1-42 ( Supplementary Fig. 1B , first panel) but as predicted, the control peptide Aβ42-1 was not detected ( Supplementary Fig. 1B , second panel). SH-SY5Y cells were thereafter fed with increasing concentrations of oAβ1-42 (125, 250 and 500 nM) and re-seeded to contain only intracellular oAβ. Using PLUS and MINUS probe-conjugated 82E1 antibody to visualize the oAβ, we found that intracellular Aβ oligomers could be detected in cells fed with 125 nM oAβ ( Quantification of the number of Duolink spots (one spot representing one oligomeric Aβ assembly) was performed using the Volocity software, and calculated as number of Duolink spots per cell. Already at 125 nM oAβ, the number of spots per cell increased significantly compared with the control peptide Aβ42-1 (Fig. 3B) , and there were significant differences between all concentrations tested. This shows that the Duolink method successfully detects intracellular oAβ at as low concentrations as 125 nM.
To test that the Duolink method does not detect monomeric Aβ, SH-SY5Y cells were also fed the non-oligomerizing peptide Aβ1-15. However, this peptide was not efficiently taken up by the SH-SY5Y cells, and could not be detected by immunocytochemistry using the 82E1 antibody ( Supplementary Fig. 1B , third panel). Instead, pure protein solutions of oAβ1-42 or Aβ1-15 were added to glass slides and let to dry. Samples were incubated with Duolink probes and reagents, followed by immunocytochemistry to detect both oligomeric and monomeric Aβ. While monomeric Aβ1-15 was detected with immunocytochemistry using the 82E1 antibody, the Duolink method did not give a positive signal ( Supplementary Fig. 1C , upper panels). On the contrary, oAβ1-42 was successfully detected with both immunocytochemistry and Duolink ( Supplementary Fig. 1C , lower panels). In conclusion, this shows that oligomeric Aβ can be specifically and sensitively detected using the Duolink method.
Low-dose γ-secretase inhibition causes intracellular accumulation of oligomeric Aβ in cortical neurons
iPSC-derived neurons were treated with low concentrations of DAPT and thereafter analysed for oAβ using the Duolink method described above. A few Duolink spots were seen in control cells (Fig. 4A, first  panel) , whereas an increased number of Duolink spots were seen in cells treated with 2 nM of DAPT (Fig. 4A, second panel) . Treatment with 20 or 200 nM DAPT did not seem to increase the number of Duolink spots C-term) shows that treatment with 2 or 20 nM DAPT does not result in increased levels of APP C-terminal fragments, whereas treatment with 200 nM of DAPT increases the levels significantly. One representative blot out of three is shown. GAPDH was used as loading control, and densitometric analysis was used to calculate the ratio of APP C-term to GAPDH. Bars represent mean ± SEM, n = 3. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. compared with control (Fig. 4A, third and fourth panel) . Analysis of the number of Duolink spots per neuron showed that treatment with 2 nM DAPT almost doubled the number of Duolink spots per cell compared with control. There was no difference between control cells and cells treated with 20 or 200 nM DAPT (Fig. 4B ). This suggests that treatment of neurons with low doses of the γ-secretase inhibitor DAPT not only results in increased secretion of long, aggregation prone Aβ peptides, but also causes an intracellular accumulation of oligomeric Aβ. 
Discussion
The failed clinical trials based on γ-secretase inhibition have led to an abandonment of these drugs in AD drug development. It is, however, still important to fully investigate the effect of partial γ-secretase inhibition, as is seen when blood and brain concentrations of γ-secretase inhibitors fluctuate due to once-a-day administration (De Strooper, 2014) . In this study, we performed a detailed investigation of the effects of partial γ-secretase inhibition on secreted Aβ peptides, as well as on intracellular oAβ accumulation, using a human iPSC-derived neuronal cell model.
We found that low-dose γ-secretase inhibition in human iPSC-derived cortical neurons increased secretion of the aggregation-prone Aβx-42, tended to increase the relative levels of longer Aβ peptides (including all peptides ending at amino acids 37 through 42) and decreased the relative levels of the shorter non-aggregation prone peptide Aβ1-34. Furthermore, treatment with 2 nM DAPT increased the number of intracellular oAβ aggregates, which are suggested to function as seeds for further Aβ aggregation and plaque formation (Gouras et al., 2010) .
Quantitative analysis of Aβx-38/40/42 indicated an increase in secretion of Aβx-42 when cells were treated with 2 and 20 nM DAPT, whereas secretion of Aβx-38 and Aβx-40 did not increase significantly. The ratio of Aβ42 over Aβ38 was significantly increased upon treatment with 20 nM DAPT, whereas the Aβ42/40 ratio was unchanged. Interestingly, although the highest dose of DAPT tested decreased the secretion of Aβ38/40/42, the ratio of both Aβ42/38 and Aβ42/40 increased, suggesting that the effect of γ-secretase inhibition is greater on shorter Aβ peptides also at higher concentrations. In support of this, it was shown that semagacestat more effectively inhibited production of Aβ1-40 than Aβ1-42 in a human trial (Lanz et al., 2006) . Taken together, these results suggest that GSIs may tilt the ratio towards longer, more aggregation-prone Aβ peptides.
As APP is cleaved into many more peptides than just Aβ38/40/42 and GSI has been shown to differently affect Aβ peptides in CSF and cultured cells, we wanted to investigate the effects of low-dose DAPT treatment on neurons further using IP-MS, enabling simultaneous detection of a variety of secreted Aβ peptides . The results showed three different types of Aβ peptide secretion patterns upon DAPT treatment. The shortest peptide, Aβ1-16, was not affected by 2 or 20 nM DAPT, but increased dramatically upon 200 nM DAPT treatment, further supporting that this peptide is not generated by γ-secretase cleavage (Portelius et al., 2010) . A similar trend was seen for the Aβ1-20 peptide, suggesting that generation of neither peptide involves γ-secretase cleavage. We have earlier shown that Aβ1-16 is produced by concerted α/β-secretase cleavage (Portelius et al., 2011) , and a similar mechanism could be true for Aβ1-20. However, both a second β-secretase (BACE2) and insulin-degrading enzyme have been suggested to cleave Aβ at position 20 . Reduced γ-secretase activity could leave more APP C-terminal fragment available for these alternative, normally less common, cleavage pathways.
A dose-dependent decrease in secretion was seen for Aβ1-34 for all doses tested, and a similar trend was observed for Aβ1-17 and 1-19 upon treatment with 20 and 200 nM DAPT. This supports that cleavage of these peptides is very sensitive to γ-secretase inhibition (Portelius et al., 2010) . All is not known regarding the generation of these peptides, but it has been suggested that Aβ1-34 is generated by a second BACE1 cleavage, requiring a preceding γ-secretase cleavage upstream (Portelius et al., 2014) , which is supported by the data presented here.
A third group of Aβ peptides, starting at Aβ5-40 and including all longer peptides up until Aβ1-42 all had a general tendency to increase A B Fig. 3 . Detection of oligomeric Aβ using a proximity ligation based assay. SH-SY5Y cells were fed with 125, 250 or 500 nM oligomeric Aβ (oAβ), or with control peptide (Aβ42-1) for 3 h, and were thereafter washed and reseeded to remove extracellular Aβ peptides. Twenty-four hours after re-seeding, cells were fixed and the intracellular oligomeric Aβ was investigated using the proximity ligation assay developed by Duolink. We hypothesised that partial inhibition of γ-secretase would result in increased levels of longer Aβ peptides as the step-wise removal of amino acids from the C-terminal end of Aβ would be hampered, based on the finding that cleavage of APP by γ-secretase starts at the ζ-and ε-sites (resulting in 46 or 49 amino acid long peptides) (Zhang et al., 2012) . Thereafter amino acids are removed step by step by γ-secretase, resulting in Aβ peptides varying from 38 to 43 amino acids in length. γ-Secretase inhibition of CHO cells overexpressing the C-terminal fragment of APP resulted in increased levels of Aβ43 and Aβ46, whereas Aβ40 decreased (Yagishita et al., 2006) . Although we found a tendency towards relative increase of all Aβ peptides from 37 amino acids of length, the increased Aβ42/38 ratio at 20 nM, and both Aβ42/38 and Aβ42/40 at 200 nM DAPT treatment could further support this idea.
As oAβ is thought to play an important role in AD pathogenesis (Benilova et al., 2012) , there is a need for specific and sensitive methods for oAβ detection in cells and tissue. Several methods have been developed for detection of oligomeric and fibrillar Aβ, although most being conformational specific and lacking specificity for Aβ (Kayed et al., 2003) , or only recognizing larger Aβ aggregates (Walsh et al., 1999) . We therefore developed a novel method, based on proximity ligation, utilizing the N-terminal specificity of the 82E1 antibody, together with the epitope blocking upon binding (Horikoshi et al., 2004) . Therefore, signals detected were specific for binding of two 82E1 antibodies, conjugated to one PLUS and one MINUS probe respectively. However, due to the even ratio of PLUS and MINUS probe labelled antibody, there is also a chance of two PLUS or two MINUS probes binding in close proximity, resulting in detection of only 50% of the possible oligomers. In spite of this, we could detect intracellular Aβ from cells fed with a starting concentration of 125 nM Aβ, hence being both a specific and sensitive assay for oAβ detection.
Intracellular accumulation of Aβ has for long been suggested to play a role in AD pathogenesis (Ferreira et al., 2007) , with endosomes being a suggested site for Aβ production (Small and Gandy, 2006) . The acidic environment within the endosomes could favour oligomerization, as could an increased production of longer, aggregation-prone Aβ peptides. We therefore went further to investigate the effects of low-dose γ-secretase treatment on intracellular accumulation of oAβ. Treatment with 2 nM DAPT resulted in an increased number of Duolink-positive oAβ spots per cell. This effect was abolished already at 20 nM DAPT and no difference was seen between 200 nM compared to control. There may be several explanations for this specific effect of 2 nM DAPT. It was recently reported that presenilin (PSEN)1 and PSEN2, the two variants of the catalytically active subunit of γ-secretase, cleave Aβ in different manners. PSEN1 cleavage also takes place at the plasma membrane, resulting in secretion of Aβ, whereas the majority of PSEN2 cleavage takes place intracellularly in late endosomes and lysosomes, resulting in intracellular accumulation of Aβ (Sannerud et al., 2016) . DAPT might, at low doses, predominantly inhibit PSEN1 and therefore increase the amounts of APP undergoing intracellular Aβ production by PSEN2, hence causing oligomerization. One could also speculate that γ-secretase inhibition generally affects intracellular and membrane-bound γ-secretase differently, resulting in this discrepancy. To further investigate if the effect on intracellular oAβ accumulation is true also for other GSI:s, as well as investigating the possible mechanisms behind this finding would be interesting. However, as the main focus of this study was to develop a method for oAβ detection and to verify this in a neuronal model, this will be the scope for a future study. In addition, it would be of interest to investigate the effects of low-dose GSI:s on oAβ secretion.
In conclusion, this study shows that exposure of human iPSC-derived neurons to low nanomolar concentrations of DAPT induces biochemical changes thought to contribute to AD pathology. This includes increased production of long, aggregation-prone Aβ peptides, together with decreased relative levels of shorter Aβ peptides, as well as accumulation of intracellular oAβ. These effects could contribute to explaining why there were no positive effects upon treatment with γ-secretase inhibitors in clinical trials.
Material and methods
Induced pluripotent stem cells and neuronal differentiation
The human iPSCs were reprogrammed from fibroblasts obtained from a healthy donor, as described previously (Sposito et al., 2015) . One iPSC line was differentiated towards cortical neurons according to the protocol by Shi et al. (2012) , as previously described (Bergström et al., 2016) . The experiments were performed using three separate differentiations.
SH-SY5Y cell culturing
SH-SY5Y neuroblastoma cells (ETCC, Sigma-Aldrich) were cultured in DMEM/F12 medium (Life Technologies) supplemented with 10% foetal calf serum (FCS) (Sigma-Aldrich) and 1% Penicillin/ Streptomycin (Hyclone, GE Health Care) in a humified chamber at 37°C with 5% CO2. The cells were differentiated using 10 μM retinoic acid (RA; Sigma-Aldrich) 5-7 days prior to experiments.
DAPT treatment and sample collection
Neurons differentiated for 75-90 days were treated with 2, 20 or 200 nM N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine tbutyl ester (DAPT; Sigma-Aldrich) in 2 ml of neural maintenance media (NMM) for 48 h. DMSO (Sigma-Aldrich) was used as vehicle control. After 48 h of DAPT treatment, conditioned NMM was collected and centrifuged at 360g for 5 min before the supernatant was transferred to new tubes and stored at − 80°C. For protein analysis, cells were washed with Dulbecco's phosphate-buffered saline (DPBS), removed by scraping, centrifuged at 400g, and DPBS was removed before storage of cell pellet at − 80°C until further analysis. For mRNA analysis, cells were washed once in DPBS and thereafter lysed directly in the well by adding 600 μl buffer RLT supplemented with 4 mM dithiothreitol (DTT). Extraction of total RNA and cDNA synthesis was performed as described previously (Bergström et al., 2016) .
Immunochemical quantification of Aβ peptides
Media concentrations of Aβx-38/40/42 were measured using the MSD Human (6E10) Abeta Triplex Assay as described by the manufacturer (Meso Scale Discovery). This assay employs C-terminally specific antibodies to capture Aβx-38/40/42, respectively, and the 6E10 antibody in combination with a SULFO-TAG-labelled anti-6E10 to quantify the peptides. The limit of detection was set to the value of the lowest standard point.
Immunoprecipitation and mass spectrometry
Cell-conditioned media collected throughout differentiation was investigated for Aβ peptides using IP-MS as described previously Briefly, 4 μg of the anti-Aβ antibodies 6E10 and 4G8 (Biolegend) was separately added to 50 μl each of magnetic Dynabeads M-280 Sheep Anti-Mouse IgG (Invitrogen) and used for immunoprecipitation (IP). Mass spectrometry (MS) measurements were performed using a Bruker Daltonics UltraFleXtreme matrix-assistedlaser-desorption/ionization time-of-flight/time-of-flight (MALDI TOF/ TOF) instrument or a Bruker Daltonics AutoFlex MALDI TOF (Bruker Daltonics). All samples were analysed in duplicate. The area under curve (AUC) of each peak was normalized against the AUC sum for all Aβ peaks in the spectrum (providing a relative MALDI signal).
Quantitative PCR
Quantitative PCR was performed using TaqMan Gene Expression Assays with FAM reporter dye in TaqMan Universal PCR Master Mix II with UNG (Applied Biosystems) according to protocol, but in a total reaction volume of 25 μl. qPCR reactions were carried out on MicroAmp 96-well optical microtitre plates on a 7900HT Fast QPCR System (Applied Biosystems), using standard settings for Standard Curve qPCR. TaqMan Gene Expression Assays for the following genes were used: Hairy And Enhancer Of Split 1, (Drosophila) (HES1: Hs00172878_m1); ribosomal protein L27 (RPL27: Hs03044961_g1); hypoxanthine phosphoribosyltransferase 1 (HPRT1: Hs02800695_m1). 2.5 ng cDNA was used in the PCR and all samples were run in duplicates. PCR results were analysed with the SDS 2.3 software (Applied Biosystems) and the relative quantity was determined using the ΔΔCT method (Livak and Schmittgen, 2001) , with the control sample as calibrator and average CT:s of RPL27 and HPRT1 as endogenous reference.
Western blot
Cells were lysed using radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris-HCl pH 7.5, 150 nM NaCl, 1 nM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitor cocktail (Complete Mini; Roche), and protein concentration was determined using the Pierce bicinchoninic acid (BCA) protein assay (ThermoFisher Scientific). Equal amounts of protein were mixed with 4× NuPAGE® LDS sample buffer (Life Technologies) and 50 mM DTT, boiled and then loaded onto a NuPAGE 4-12% Bis-tris gel. For oAβ, 1 μM samples were diluted 1:20, mixed with 4× sample buffer, and loaded onto a NuPAGE 4-12% Bis-tris gel. Proteins were blotted onto a 0.2 μm nitrocellulose membrane using semi-dry technique. Membranes were blocked using 5% milk before incubation with primary antibody over night at 4°C. Primary antibodies used were anti-C-terminal APP (1:5000; Millipore 171,610) and anti-β-Amyloid 1-16 (1:1000, clone 6E10; Biolegend). After washing, membranes were incubated with a horseradish peroxidase (HRP)-linked Anti-Rabbit IgG or HRP-linked Anti-Mouse IgG (both 1:2000; Cell Signaling Technology). Proteins were visualized using the SuperSignal® West Dura Extended Duration Substrate (ThermoFisher Scientific) by the ChemiDoc XRS + and Image Lab 3.0 software (both from Bio-Rad Laboratories). Membranes were stripped using Restore stripping buffer (ThermoFisher Scientific) and re-probed using HRP-conjugated glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1:20,000; Novus biological). Densitometry quantification was performed using ImageJ (NIH).
Aβ oligomerization
Aβ1-15, 1-42 and 42-1 (all from Bachem) were dissolved to 443 μM in 10 mM NaOH, aliquoted and stored at −80°C until further use. Aβ peptide in 10 mM NaOH was mixed with 10 mM HCl and DPBS in a 1:1:2 ratio in protein LoBind tubes (Eppendorf) and incubated for 48 h at 37°C.
Treatment of cells with Aβ
Oligomerized Aβ1-42 and Aβ42-1 were delivered to RA differentiated SH-SY5Y cells as previously described (Domert et al., 2014) . Briefly, oAβ was dissolved in serum free DMEM/F12 (125, 250 or 500 nM for Aβ1-42, 500 nM for Aβ42-1) and cells were incubated with oAβ containing medium for 3 h. Thereafter, cells were washed with PBS, incubated with fresh PBS for 10 min at 37°C, trypsinized, resuspended in DMEM/F12 media and centrifuged at 400g for 5 min. Thereafter, the cells were resuspended in fresh DMEM/F12 media and re-seeded onto glass coverslips.
Immunocytochemistry
Aβ-fed cells were fixed with 4% PFA 24 h after re-seeding. Thereafter, the samples were blocked with 5% donkey serum (SigmaAldrich) in 0.3% Triton-X100 in TBS for 1 h at room temperature (RT). The antibody (Anti human Aβ, clone 82E1; IBL International) was diluted 1:100 in block buffer and incubated over night at 4°C. Secondary goat anti mouse Alexa 562-antibody (Life Technologies) was diluted 1:400 in block buffer and incubated for 1 h at RT. Samples were incubated with cell mask (Life Technologies; 1:20,000 in TBS) for 10 min (for visualization of cytosol) and after washing, the samples were mounted onto microscope slides using prolong gold antifade mounting media (Life Technologies).
Duolink assay
Lyophilized anti human Aβ antibody (clone 82E1, IBL international) in PBS without BSA or preservatives was reconstituted in H 2 O to a concentration of 1 mg/ml. Thereafter one aliquot of the antibody was conjugated to PLUS probe, and one to MINUS probe (all reagents from Sigma-Aldrich if not stated otherwise) respectively, according to the manufacturer's instructions. Samples were fixed in 4% PFA in PBS and blocked using 5% donkey serum in TBS with 0.3% triton-X100. Antibody/probe was diluted 1:1000 (for PLUS and MINUS respectively) in block buffer containing 1 × Duolink assay reagent. Samples were incubated with antibody/probe solution over night at 4°C. The remaining steps were performed according to the manufacturer's instructions using Duolink wash buffers and detection reagent red. After polymerase reaction, samples were incubated with cell mask (1:20,000), and mounted using Duolink mounting media with DAPI and sealed with nail polish. Samples were stored at −20°C until further analysis.
Confocal microscopy and image analysis
The samples were analysed using a Zeiss LSM700 inverted confocal microscope with 40-63× objectives and the ZEN2000 software (Zeiss). From each sample, 10 images were captured in a randomized manner. Image analysis was performed using the Volocity 6.3 Software (PerkinElmer). Duolink spots were detected based on fluorescence intensity and size. DAPI-stained nuclei were detected based on fluorescence and size. The number of Duolink spots and number of nuclei per image was analysed and the number of Duolink spots per nuclei (cell) was calculated.
Statistical analysis
All results where statistical analysis is performed are presented at means ± S.E.M. from three independent repeats. One-way ANOVA was used to compare differences between groups, followed by Dunnett's correction for multiple comparisons. All statistical analyses were performed using Graph Pad Prism 6.0 (GraphPad Software Inc.).
